---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-020009"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:40:02.154668+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology Q1 net loss narrows to $65.3M; CFO stepping down; pipeline catalysts ahead

## Summary
- Net loss of $65.3M ($0.48 loss per share) vs $140.9M ($1.06) in Q1 2023; revenue $56.4M down 10.5% YoY.
- Cash, equivalents & investments $1.51B, down $118M in Q1; FY2024 R&D+SG&A guidance reaffirmed $650-680M.
- CFO Sung Lee stepping down effective May 3; successor search initiated.
- SOLSTICE hepatitis delta late-breaker abstract accepted at EASL June; 24-week data expected Q4 2024.
- MARCH hepatitis B data and HIV VIR-1388 immunogenicity data expected H2 2024.

## SEC filing metadata
- accession: 0001628280-24-020009
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828024020009/0001628280-24-020009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828024020009/vir-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-020009
- JSON: https://secwatch.observer/filing/0001628280-24-020009.json
- Plain text: https://secwatch.observer/filing/0001628280-24-020009.txt

## Key facts
- Earnings Releases
  Vir Biotechnology, Inc. reported first quarter ended March 31, 2024 results: revenue $56.4 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $56.4 million
  - Result: reported results
  source text: cash equivalents and investments declined by approximately $118 million during the first quarter of 2024. Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023. Revenues were comprised of the following components: Three Months Ended March 31, 2024 2023 % Change (in millions)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828024020009/0001628280-24-020009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.